Press release
Investigation announced for Long-Term Investors in shares of Eli Lilly and Company (NYSE: LLY)
An investigation on behalf of investors in Eli Lilly and Company (NYSE: LLY) shares over potential wrongdoing at Eli Lilly and Co.
Investors who purchased shares of Eli Lilly and Company (NYSE: LLY) a have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Eli Lilly and Company (NYSE: LLY officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
In August 2020, Eli Lilly and Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
On October 13, 2020, the trial's sponsor, the National Institute of Allergy and Infectious Diseases ("NIAID") recommended that the trial be paused after an analysis of safety data found "an overall difference in clinical status between the group receiving LY-CoV555 and the group receiving saline placebo."
Shares of Eli Lilly and Company (NYSE: LLY) declined from $157.15 per share on October 9, 2020 to as low as $142.24 per share on October 19, 2020.
Those who purchased shares of Eli Lilly and Company (NYSE: LLY) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Eli Lilly and Company (NYSE: LLY) here
News-ID: 2184159 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Eli
Alzheimer's Disease Market: Epidemiology, Therapies, Companies, DelveInsight | B …
According to DelveInsight analysis, nearly 2.4 million males and 5 million females were affected with Alzheimer's disease in the US in 2024. DelveInsight estimates that these numbers will increase by 2034.
The market for Alzheimer's Disease is anticipated to expand in the coming years, driven by the development of emerging therapies.
DelveInsight has released a comprehensive report titled "Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast 2034", providing detailed analysis of…
Epic Eli Returns with Emotionally Charged Single 'Blindfold'
Independent hip-hop artist and genre-blurring storyteller Epic Eli is back with "Blindfold," a deeply personal and reflective new single arriving August 1st on all major streaming platforms. Stripped-back yet impactful, "Blindfold" trades heavy synths for vulnerability, beginning with raw acoustic guitar chords before gradually building into a moody, modern trap beat - a sonic metaphor for the emotional unraveling that unfolds in the lyrics.
"Blindfold" explores the disillusionment that follows emotional…
Eli Primmer Has done it again!
Eli Primmer released his latest single ""Running This town" earlier today (April 5th, 2024) And even though it's an a capella song, it immediately became a hit!
Fans have commented that this song is their NEW FAVOURITE, and that they're even more excited for the release of Eli Primmer's upcoming album! ""Running this town" is Primmer's way of telling the haters to ""back off" and how he's running this town so…
Eli Primmer's new album!
Eli Primmer Set to Release New Album, "Timeless Happiness". Singer-songwriter Eli Primmer has announced the forthcoming release of his highly anticipated new album, "Timeless Happiness." The album is scheduled to drop on June 23, 2024, and is a captivating blend of pop and R&B sensibilities. Encompassing 11 tracks, "Timeless Happiness" showcases Primmer's signature blend of infectious melodies, heartfelt lyrics, and production excellence. The album is a journey through love, loss,…
Cannabis Testing Market by Top Key Players - Agilent Technologies, Perkin Elmer, …
Cannabis testing defines various drug test methods for the usage of cannabis in medical prescription, sports medicine, and law. The rapidly increasing applications of cannabis (marijuana) in mainstream medicine such as pain management is poised to increase demand for cannabis testing measures.
Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2872404?utm_source=RK&utm_medium=OPR
The Cannabis Testing Market research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and…
Global Raloxifene Hydrochloride Market 2017 - Eli Lilly, InvaGen Pharmaceuticals
The report entitled Global Raloxifene Hydrochloride Market 2017 presents key insights into the global Raloxifene Hydrochloride market along with the latest up-to-date industry details and forthcoming Raloxifene Hydrochloride industry trends, which will assist the readers to focus on product specification and end users driving the overall market revenue and profitability.
Report Keynotes:
The main motive of the report on "Global Raloxifene Hydrochloride Market 2017" is to study comprehensive details of the market…
